Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 6785 in Moderate to Severe COPD
NCT01966549Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2013
- Primary completion
- Sep 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease (COPD), sponsored by Janssen Pharmaceutical. Started Nov 2013; status: completed.
02
Drugs
CNTO 6785
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01966549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01966549.